# Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference
Ticker: BMY
Company: BMYBristol-Myers Squibb Company
Source: BMYBristol-Myers Squibb Company
Published: 2026-06-25 13:46 EST
Original Source URL: https://news.bms.com
## Summary

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026. The company will take part in a fireside chat beginning at 2:00 p.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com . An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients’ Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram . corporatefinancial-news Media: media@bms.com Investors: investor.relations@bms.com Source: Bristol Myers Squibb

## Article Body
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026.

The company will take part in a fireside chat beginning at 2:00 p.m. ET.

Investors and the general public are invited to listen to the session by visiting http://investor.bms.com . An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn , X , YouTube , Facebook and Instagram .

corporatefinancial-news

Source: Bristol Myers Squibb

Media downloads:

Categories: Press Releases
## Recent Company News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-13 10:59 EST — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — [Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-report-results-for-second-quarter-2026-on-july-30-2026) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — [Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease](https://biopharmsignal.com/news/BMY/mariska-hargitay-partners-with-bristol-myers-squibb-for-investigating-myeloma-awareness-campaign-to-honor-her-father-20-years-after-losing-him-to-the-disease) — Source: BMYBristol-Myers Squibb Company
- 2026-06-25 13:46 EST — [Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma](https://biopharmsignal.com/news/BMY/izalontamab-brengitecan-iza-bren-demonstrates-statistically-significant-and-clinically-meaningful-improvements-in-overall-survival-and-progression-free-survival-in-patients-with-triple-negative-breast-cancer-and-esophageal-squamous-cell-carcinoma) — Source: BMYBristol-Myers Squibb Company
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)